FY2025 Earnings Estimate for ENTA Issued By Leerink Partnrs

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Leerink Partnrs lifted their FY2025 earnings estimates for Enanta Pharmaceuticals in a research note issued to investors on Monday, December 9th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will post earnings of ($4.70) per share for the year, up from their prior estimate of ($4.95). The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.81) per share. Leerink Partnrs also issued estimates for Enanta Pharmaceuticals’ FY2026 earnings at ($2.95) EPS and FY2027 earnings at ($1.70) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The company had revenue of $14.60 million during the quarter, compared to analysts’ expectations of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. Enanta Pharmaceuticals’s quarterly revenue was down 22.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.33) EPS.

ENTA has been the topic of a number of other reports. JMP Securities restated a “market outperform” rating and issued a $21.00 target price (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. Finally, Robert W. Baird dropped their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.50.

Enanta Pharmaceuticals Stock Down 10.1 %

NASDAQ ENTA opened at $6.29 on Thursday. Enanta Pharmaceuticals has a fifty-two week low of $6.25 and a fifty-two week high of $17.80. The business has a fifty day moving average of $10.33 and a 200-day moving average of $11.96. The stock has a market cap of $133.31 million, a price-to-earnings ratio of -1.15 and a beta of 0.49.

Institutional Trading of Enanta Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ENTA. Krensavage Asset Management LLC boosted its position in shares of Enanta Pharmaceuticals by 19.7% in the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after buying an additional 246,736 shares during the period. Geode Capital Management LLC lifted its position in Enanta Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock worth $4,946,000 after acquiring an additional 14,575 shares in the last quarter. State Street Corp boosted its holdings in Enanta Pharmaceuticals by 6.4% in the 3rd quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock worth $4,662,000 after acquiring an additional 27,147 shares during the period. Erste Asset Management GmbH acquired a new stake in Enanta Pharmaceuticals in the third quarter valued at approximately $1,243,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Enanta Pharmaceuticals during the third quarter valued at approximately $903,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Jay R. Luly sold 5,142 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the transaction, the chief executive officer now owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 13.64% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.